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A novel immunofluorescent 
assay to investigate oxidative 
phosphorylation deficiency 
in mitochondrial myopathy: 
understanding mechanisms and 
improving diagnosis
Mariana C. Rocha1,2,*, John P. Grady2,*, Anne Grünewald2, Amy Vincent2, Philip F. Dobson1, 
Robert W. Taylor2, Doug M. Turnbull1,2 & Karolina A. Rygiel1,2
Oxidative phosphorylation defects in human tissues are often challenging to quantify due to 
a mosaic pattern of deficiency. Biochemical assays are difficult to interpret due to the varying 
enzyme deficiency levels found in individual cells. Histochemical analysis allows semi-quantitative 
assessment of complex II and complex IV activities, but there is no validated histochemical assay to 
assess complex I activity which is frequently affected in mitochondrial pathology. To help improve 
the diagnosis of mitochondrial disease and to study the mechanisms underlying mitochondrial 
abnormalities in disease, we have developed a quadruple immunofluorescent technique enabling 
the quantification of key respiratory chain subunits of complexes I and IV, together with an 
indicator of mitochondrial mass and a cell membrane marker. This assay gives precise and objective 
quantification of protein abundance in large numbers of individual muscle fibres. By assessing muscle 
biopsies from subjects with a range of different mitochondrial genetic defects we have demonstrated 
that specific genotypes exhibit distinct biochemical signatures in muscle, providing evidence for 
the diagnostic use of the technique, as well as insight into the underlying molecular pathology. 
Stringent testing for reproducibility and sensitivity confirms the potential value of the technique for 
mechanistic studies of disease and in the evaluation of therapeutic approaches.
Defects of mitochondrial oxidative phosphorylation (OXPHOS) are found in a wide range of human 
pathologies, either as a primary cause of disease through genetic defects involving either the mito-
chondrial (mtDNA) or nuclear genome1,2, or secondary when there are other prominent pathological 
processes such as inflammation (multiple sclerosis3, inclusion body myositis4) or degenerative features 
(Parkinson’s disease5).
Skeletal muscle is frequently affected by both primary and secondary mitochondrial defects. 
Mitochondrial myopathies are progressive and clinical features include chronic progressive external oph-
thalmoplegia, rhabdomyolysis, muscle fatigue and severe proximal weakness6. Muscle is also commonly 
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affected in patients with a multisystem phenotype7,8. Involvement of mtDNA usually leads to mosaic 
deficiency of the OXPHOS in muscle; mtDNA is present in multiple copies in cells and mutations are 
frequently heteroplasmic (mixed mutated and wild-type mtDNA within an individual cell). Biochemical 
defects are often only apparent in cells with high levels of mutated mtDNA9,10.
Current diagnostic algorithms for investigating and diagnosing mitochondrial disease use histochem-
ical and biochemical assessment of OXPHOS activities in clinically-affected tissues11. Biochemical assays 
measure activity of each individual OXPHOS enzyme complex (complex I–V) in homogenised muscle 
tissue11. Whilst they are very useful for assessment of wide-spread mitochondrial defects, they may fail 
to detect more subtle OXPHOS deficiencies, especially when only a few myofibres are involved. They also 
require substantial quantities of muscle (> 50 mg) which are not always available.
The histochemical assessment of cytochrome c oxidase (Complex IV, COX) and succinate dehydro-
genase (Complex II, SDH) activities are standard methodologies to assess OXPHOS function in tissue 
cryosections, interrogating the activities of these two complexes in individual cells12,13. Though valuable 
for detecting the mosaic OXPHOS deficiency observed in many mitochondrial myopathies, myofibre 
classification is subjective, qualitative and prone to inter-observer variability14,15. Further, there are no 
histochemical techniques to assess other OXPHOS complexes, in particular complex I, which is com-
monly affected in mitochondrial disease16,17, and often occurs at initial stages of cell damage, a potentially 
valuable early indicator of pathology18.
As well as diagnostic applications, histochemical and biochemical assays have been used to investigate 
mitochondrial disease progression19,20 and to assess experimental therapeutic approaches in mitochon-
drial disease21,22. The effects of exercise and other potential therapies on mitochondrial function may be 
subtle, thus sensitive and quantitative methods are needed.
To overcome the limitations of currently available methods we have developed an objective and 
semi-automated technique allowing quantification of mitochondrial dysfunction in individual myofibres.
Methods
Cohort clinical characteristics. Muscle biopsies were obtained from twenty-two patients with clini-
cally and genetically-characterised mitochondrial disease of both mtDNA and nuclear genetic origin, and 
from four healthy and disease controls (Table 1). All disease controls showed normal muscle histology, 
oxidative enzyme histochemistry, and OXPHOS biochemical activities11.
Ethical approval was granted by the Newcastle and North Tyneside Local Research Ethics Committees 
(reference 09/H0906/75). The experiments were carried out in accordance with the approved guidelines. 
Written informed consent was received from participants prior to inclusion in the study.
COX/SDH histochemistry. Sequential COX/SDH histochemistry (COX/SDH) was carried out 
according to an established protocol12. Briefly, frozen muscle sections (10 μ m) were dried, washed in 
PBS (OXOID, Basingstoke), and incubated with COX solution for 45 min at 37 °C. Following a PBS wash 
the sections were overlaid with SDH solution and incubated for 40 min at 37 °C.
Quadruple immunofluorescence. Quadruple immunofluorescence was carried out on transverse 
muscle sections (10 μ m) using antibodies detecting subunits of OXPHOS complexes (Supplementary 
Table S1). Complex I was detected using an antibody against subunit NDUFB823, and Complex IV 
using an antibody to mtDNA encoded subunit I (COX-I). Mitochondrial mass was quantified using an 
antibody to porin, an outer mitochondrial membrane voltage-gated ion channel. Laminin, a basement 
membrane glycoprotein, was used to label the myofibre boundaries (Supplementary Table S1). Briefly, 
the sections were fixed in cold 4% paraformaldehyde (Sigma) for 3 min and permeabilised in a methanol 
(Fisher) gradient (10 min 70% methanol, 10 min 95% methanol, 20 min 100% methanol, 10 min 95%. 
methanol and 10 min 70% methanol). Non-specific protein interactions were blocked with 10% normal 
goat serum (Sigma) and incubated with the primary antibodies in a humidified chamber at 4 °C over-
night (Supplementary Table S1). Following washes in TBST (Sigma), the sections were incubated with 
the secondary antibodies for 2 h at 4 °C and subsequently with streptavidin conjugated with Alexa 647 
(Life Technologies) for 2 h at 4 °C (Supplementary Table S1). The sections were washed and mounted in 
Prolong Gold (Sigma). No-primary antibody controls, incubated only with anti-laminin antibody, were 
processed for each muscle sample.
Image acquisition. Brightfield and fluorescent images were acquired at 20× magnification using 
a Zeiss Axio Imager M1 and Zen 2011 (blue edition) software, with a monochrome Digital Camera 
(AxioCam MRm) and filter cubes for Alexa Fluor dyes at 405 nm, 488 nm, 546 nm and 647 nm wave-
lengths, for laminin, COX-I, porin and NDUFB8 respectively. Exposure times for each channel were set 
to avoid pixel saturation and maintained between cases. Images were recorded as 16-bit czi files. Between 
447 and 2400 fibres were imaged according to the muscle section size.
To assess reliability of immunofluorescence: fluorescent images were acquired at 20× magnification 
using a Zeiss Axio Imager Z2 with a motorized stage and AxioVision (Release.4.8.2) software, with 
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Subjects Gender Age Clinical information Genetic defect
Patients with known mutations affecting complex I and IV specifically
 P1 Male 1y Encephalopathy, seizures, hypotonia, developmental delay, central apnoeas
Compound heterozygous 
LRPPRC mutations 
(manuscript in preparation)
 P2a Male 20y Exercise-induced muscle weakness and lactic acidosis
m.4175G > A (p.Trp290*) 
MTND1 mutation
Single, large-scale mtDNA deletion
 P3 Female 22y CPEO single, large-scale mtDNA deletion
 P4 Female 29y CPEO and bilateral ptosis single, large-scale mtDNA deletion
 P5 Female 39y CPEO single, large-scale mtDNA deletion
 P6 Female 74y CPEO single, large-scale mtDNA deletion
Autosomal disorders of mtDNA maintenance
 P7b Male 36y
Severe PEO, ptosis, proximal muscle 
weakness, facial weakness, scapulae 
winging, low BMI, hypogonadism and 
osteoporosis.
multiple mtDNA 
deletions; autosomal 
recessive p.(Thr144Ile) 
and p.(Gly273Ser) RRM2B 
mutations
 P8c Female 43y
Severe PEO, asymmetrical ptosis, 
proximal and distal muscle weakness, 
ataxia, SNHL, facial weakness, low 
BMI, leukoencephalopathy and 
depression
multiple mtDNA deletions; 
autosomal recessive 
p.(Arg186Gly) and 
p.(Thr218Ile) RRM2B 
mutations
 P9 Male 47y CPEO and bilateral ptosis
multiple mtDNA deletions; 
autosomal dominant 
p.(Asp104Gly) SLC25A4 
mutation
 P10 Female 54y CPEO, ptosis, muscle weakness
autosomal dominant 
p.(Gln458His) PEO1 
mutation
 P11 Male 60y CPEO and bilateral ptosis multiple mtDNA deletions; nuclear basis unresolved
m.3243A > G MT-TL1 mutation
 P12 Female 25y Exercise intolerance, ptosis m.3243A > G MT-TL1 mutation
 P13 Female 40y Exercise intolerance and mild deafness
m.3243A > G MT-TL1 
mutation
 P14 Female 42y
Epilepsy, bilateral sensorineural 
hearing loss, diabetes, gastrointestinal 
complications
m.3243A > G MT-TL1 
mutation
 P15 Female 47y Modest exercise intolerance m.3243A > G MT-TL1 mutation
 P16 Male 53y CPEO m.3243A > G MT-TL1 mutation
Other mt-RNA mutations
 P17d Female 13y CPEO, ptosis, proximal myopathy m.5690A > G MT-TN mutation
 P18 Female 18y Seizures, deafness, retinopathy
Novel 
m.16021_16022detCT MT-
TP mutation (unpublished)
 P19 Male 33y Mitochondrial myopathy m.10010T > C MT-TG mutation
 P20 Female 35y Mild weakness m.14709T > C MT-TE mutation
 P21 Male 63y Pure exercise intolerance, prominent exertional dyspnea
m.5543T > C MT-TW 
mutation
 P22 Male 76y Muscle pain and weakness m.3243A > T MT-TL1 mutation
Healthy control
 HC1 Female 20y Biopsy obtained during orthopaedic surgery. n.a.
Continued
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identical camera and filters as above. Images were recorded as zvi files and processed by Zen 2011 (blue 
edition) software using the stitching function.
Subjective assessment of myofibres (visual classification). To assess the correlation between 
enzyme activity and protein abundance, visual classification of COX/SDH was performed using a stere-
ological workstation with a modified light microscope (Olympus, Japan), motorized stage, CCD colour 
camera and stereology software (Stereo Investigator, MBF Bioscience, USA).
To assess the limitations of COX/SDH, a third investigator imaged different areas of two biopsies and 
selected 100 myofibres for each patient. Both investigators 1 and 2 visually classified labelled myofibres 
in COX/SDH images (at 20× magnification).
Objective assessment of myofibres. 
Densitometry measurements. Fluorescent images were analysed using IMARIS software (Bitplane). 
Segmentation was performed to isolate individual myofibres (Supplementary Fig. S1). A first surface 
was created over the 405 nm channel and used to form a laminin mask. Following this, a second surface 
was created based on the masked 405 nm channel. As a result, multiple surfaces were formed over indi-
vidual muscle fibres. Unwanted areas (such as vessels or background) were removed in a filtering step. 
The mean optical density (OD) of 488, 546 and 647 nm channels were automatically measured in each 
individual muscle fibre in a scale ranging from 0 (brightest pixels) to 65,535 (darkest pixels) intensity 
units (ODCOX-I, ODNDUFB8 and ODporin). The mean ODs of the no primary control (OD488, OD546, 
OD647) were measured to determine the levels of non-specific fluorescence.
Data analysis. For each myofibre, ODCOX-I, ODNDUFB8, and ODporin, were corrected for back-
ground signal. ODCOX-I and ODporin values were corrected by subtracting the mean OD488 and 
mean OD546 of the no primary control respectively. ODNDUFB8 was corrected according to mito-
chondrial mass: fibres were sorted into one hundred groups according to the ODporin percentile, and 
corrected using the mean OD647 of the matching ODporin percentile group from the no primary con-
trol. Background corrected OD values were log transformed (yielding ODCOX-IT, ODNDUFB8T and 
ODporinT) to normalize the data.
The parameters (mean and standard deviation, SD) describing the distribution of ODporinT in the 
control population (healthy and disease controls) was determined as described in the statistical meth-
ods, as well as parameters describing the linear relationship between ODCOX-IT versus ODporinT and 
ODNDUFB8T versus ODporinT. Z-scores were determined for ODporinT (porin_Z), as well as Z-scores 
for NDUFB8 (NDUFB8_Z) and COX-I (COX-I_Z) based on the expected level of each according to the 
porin level.
Fibres were classified into groups according to porin Z-score: "very low" (porin_Z < − 3SD), “low" 
(porin_Z between − 3SD and − 2SD), “normal" (porin_Z between − 2SD and + 2SD), "high" (porin_Z 
between + 2SD and + 3SD) and “very high" (porin_Z above + 3SD). Fibres were similarly classified based 
on SD limits into groups of NDUFB8 and COX-I levels (normal if Z-scores > − 3SD; intermediate(+ ) if 
Z-scores between − 3SD and − 4.5SD; intermediate(− ) if Z-scores between − 4.5SD to − 6SD; deficient 
if Z-scores < − 6 SD). The upper SD boundary of COX-I and NDUFB8 deficient groups were set as the 
highest NDUFB8_Z and COX-I_Z of red-appearing fibres on quadruple immunofluorescence (express-
ing porin but neither COX-I nor NDUFB8) from patients P11 and P17. These limits were confirmed 
and validated when immunofluorescence was performed on a serial section on a different day to assess 
reproducibility of the technique. The lower SD boundaries of COX-I and NDUFB8 positive groups were 
defined by the control group distribution.
Statistical analyses. All statistical analyses were carried out using R 3.1.324.
Subjects Gender Age Clinical information Genetic defect
Disease controls
 DC1 Male 4y Hypotonia and fatigue n.a.
 DC2 Male 18y Leukodystrophy and raised creatine kinase n.a.
 DC3 Female 20y Tremor and spasticity n.a.
Table 1.  Clinical information from patients included in this study. Key: age = age when biopsied; 
y = years old; mtDNA = mitochondrial DNA; PEO = progressive external ophthalmoplegia; CPOE = chronic 
CPEO; BMI = body mass index; a,b,c,dpublished cases. aGorman et al. (2015) in press. bP19 and. cP20 in 
Pitceathly et al. (2012). dP3 in Blakely et al. (2013).
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All data are presented as percentage (%) of the total number of myofibres, with n corresponding to 
the number of myofibres analysed.
Determination of porin, COX-I and NDUFB8 distribution in controls. The Box-Cox transformation25 
identified the log transformation as optimal to achieve normality of the background corrected data. This 
was confirmed using both visual inspection and normality tests (Shapiro-Wilk26 and D’Agostino-Pearson’s 
omnibus test27).
The control group was created by simple random sampling of equal numbers of fibres from each of 
the control subjects, both healthy and disease controls. The control with the lowest number of fibres 
was determined and used to set the number of fibres randomly chosen in remaining controls. From 
the selected fibres, ODCOX-IT versus ODporinT and ODNDUFB8T versus ODporinT were plotted 
(Supplementary Fig. S2A and 2B). Linear regressions of ODCOX-IT and ODNDUFB8T (dependent var-
iables) against ODporinT (independent variable) were performed (Supplementary Fig. S2A and 2B), val-
idated to ensure the residuals of the regression were normally distributed (Supplementary Fig. S2C and 
2D) and the standard error of estimate was determined; this enabled the estimate of deviation of COX-I 
and NDUFB8 levels in each fibre from the predicted level according to the porin level.
Statistical validation of porin, COX-I, and NDUFB8 distribution in controls. The Z test for two population 
proportions was applied to assess the correlation of COX activity and COX-I abundance (Supplementary 
Table S2), and assess the reproducibility and reliability (Supplementary Table S3) of the quadruple immu-
nofluorescence assay.
Results
Assessing the potential advantage of quadruple immunofluorescence over COX/SDH histo-
chemistry. We first studied two patients with inherited genetic defects that lead to isolated deficiency 
of complex IV (P1) or complex I (P2), and two patients with mosaic COX deficiency (P11 and P17) 
(Table  1 and Fig.  1). Serial sections from these patients were assessed using COX/SDH and quadru-
ple immunofluorescence. Based on the COX/SDH, three categories of myofibres were identified: COX-
positive, COX-intermediate, and COX-deficient28.
The patient with LRPPRC mutations (P1) displayed uniform deficiency of COX-I consistent with the 
COX/SDH assay (Fig. 1). The patient with m.4175G > A MT-ND1 (P2) had normal COX-I abundance 
and no observed deficiency following COX/SDH, but showed a marked defect in NDUFB8 abundance 
(Fig.  1). In both patients with mosaic deficiency of COX (P11 and P17), an agreement between COX 
activity and COX-I abundance was observed. Fibres with no discernible COX activity showed a complete 
absence of COX-I protein, those with lower COX activity had similarly decreased COX-I abundance, and 
fibres with enhanced COX activity showed the highest COX-I abundance. Interestingly, fibres exhibiting 
a subtle decrease in COX activity were barely distinguishable as abnormal based on COX/SDH (Fig. 1: 
fibres marked ″ 4″ ) although clearly abnormal in images of the merged COX-I/porin immunoreaction. 
All fibres highlighted in Fig. 1 showed decreased or absent NDUFB8.
Correlation of COX/SDH histochemistry with quadruple immunofluorescence. We investigated 
four different patients with mosaic COX deficiency evident with COX/SDH (P5, P9, P12, P19 (Table 1)). 
These patients were chosen because all muscle biopsies showed a distinction between COX-deficient 
and COX-intermediate fibres. Serial sections from these four patients were subjected to COX/SDH and 
quadruple immunofluourescence. Myofibres were visually classified based on COX/SDH; for improved 
classification the COX-intermediate group was subdivided into COX-intermediate(+ ) (Fig. 1, fibres ″ 4″ 
– grey cells) and COX-intermediate(− ) (Fig. 1, fibres marked ″ 2″ – light blue/purple cells). The immu-
nofluorescence was objectively classified based on COX-I and porin (Fig. 2A).
The difference between the objective COX-I classification and COX/SDH visual classification was 
always lower than 5 percentage points, but the difference between techniques was not systematic over- or 
under-estimation (Fig. 2B, Supplementary Table S2).
Challenges of COX/SDH histochemistry in assessing degree of respiratory deficiency. We 
investigated muscle biopsies from two patients which were difficult to visually assess, due to uneven 
labelling and an apparent continuous spectrum of COX activity: P13 and P16 (Table 1). Serial sections 
were assessed using COX/SDH and quadruple immunofluourescence (Fig. 3A). One hundred myofibres 
were selected and visually categorised by two researchers independently into one of the four categories: 
COX-positive, COX-intermediate(+ ), COX-intermediate(− ) and COX-deficient. The same 100 fibres 
were objectively categorised based on COX-I and porin levels.
Analysis of both patients P13 and P16 revealed marked differences in fibre classification between 
the investigators, but importantly, this was also internally inconsistent; investigator 1 underestimated 
COX deficiency in patient P13 and overestimated it in patient P16, whereas the opposite was true for 
investigator 2 (Fig. 3B).
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Reproducibility and reliability of the quadruple immunofluorescent technique. We tested 
whether the immunofluorescent analysis of serial muscle sections from five patients (P1, P2, P11, P17 
and P18) gave comparable results when sections are processed through the methodological protocol 
(quadruple immunofluorescence, imaging and IMARIS analysis) on two separate occasions (“day 1” and 
Figure 1. Comparison of COX/SDH histochemistry with complex I, IV and porin immunofluorescence. 
COX/SDH and quadruple immunofluorescence were performed in serial muscle sections from patients: 
P1, P2, P11 and P17. Fluorescent detection was used to visualise: complex IV subunit I (COX-I) - green 
(488 nm), complex I subunit (NDUFB8) - purple (647 nm) and porin (mitochondrial mass) - red (546 nm). 
P1 (LRPPRC mutations) shows widespread COX deficiency whereas P2 (m.4175G > A MT-ND1 mutation) 
shows widespread NDUFB8 deficiency and preserved COX activity. Both P11 and P17 show mosaic COX 
deficiency. Selected muscle fibres demonstrate: (1) COX deficiency (COX-deficient fibres) with absent 
COX-I immunoreactivity, (2) decreased COX activity (COX-intermediate fibres) and decreased level of 
COX-I abundance, (3) normal COX activity (COX-positive fibres) and COX-I level but absent NDUFB8 
immunoreactivity, (4) apparently normal COX activity and low level of COX-I immunoreactivity. All fibres 
highlighted show down-regulated levels of NDUFB8 abundance. P1 is a paediatric case and thus has smaller 
fibre size than the other cases. Scale bars measure 50 μ m.
www.nature.com/scientificreports/
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Figure 2. Correlation between COX activity and COX-I immunodetection. (A) COX/SDH histochemistry 
(top) and quadruple immunofluorescence (bottom, COX-I - green, NDUFB8 - purple, porin - red and 
laminin - white) were performed on serial muscle sections from patients P5, P9, P12 and P19. (B) Visual 
classification (COX/SDH) and objective classification (COX-I and porin immunodetection) results. 
Fibres were classified as COX (activity/protein abundance) positive (beige), intermediate(+ ) (light 
beige), intermediate(− ) (light blue) or deficient (blue). Fibres counted (n = visual/immunodetection): P5 
(n = 1103/841); P9: (n = 1395/1071); P12: (n = 1887/1740) and P19: (n = 956/769). Visually classified COX 
deficiency was overestimated in P5 by 3.6 percentage points, underestimated in P19 by 4.4 percentage points, 
underestimated in P12 by 4.1 percentage points, and consistent in P5, as compared to objective classification. 
Scale bars measure 50μ m.
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“day 2” 2 months apart) (Table 2). The results were highly consistent. The differences in the percentage 
of fibres constituting one of the four categories between the two time points varied between 0.1 and 9 
percentage points.
In order to evaluate the reliability of the method, we assessed whether the immunofluorescent analysis 
from the same tissue section (P8) gave comparable results when data are collected (imaging and IMARIS 
analysis) on two separate occasions by two investigators at a 15-day interval (Fig.  4). The results were 
almost identical for complex IV: the greatest difference of less than 4 percentage points was noted for 
Figure 3. Inter- and intra-observer variability of visual classification. (A) COX/SDH (top) and quadruple 
immunofluorescence (bottom: COX-I - green, NDUFB8 - purple, porin - red and laminin - white) were 
performed in two serial muscle sections from patients P13 and P16. 100 myofibres from each patient were 
visually classified (COX/SDH) by two independent investigators, and objectively classified (COX-I and 
porin immunodetection). (B) Bar graphs show the percentage of COX-positive (beige), intermediate(+ ) 
(light beige), intermediate(− ) (light blue) or deficient (blue) based on visual classification by investigator 
1 and 2 (first two bars) and objective classification (last bar). In patient P13, both investigators identified 
the majority of COX-positive cells correctly (40% versus 42% using immunofluorescence) but differed in 
other categories. In patient P16, the investigators differed markedly in all categories. Importantly, both 
investigators demonstrated a high degree of internal inconsistency.
www.nature.com/scientificreports/
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COX-I positive and intermediate (+ ) groups (Fig. 4A, Supplementary Table S3). The results for complex 
I differed slightly more with the maximum discrepancy within the deficient fibres of 5.7 percentage 
points (Fig. 4B, Supplementary Table S3).
Biochemical phenotype in genetically-defined mitochondrial myopathies. Quadruple immu-
nofluorescence was performed in twenty-two patients with genetically-determined mitochondrial disease 
(P1-P22) (Table 1). Representative cases are shown in Figs 1 and 5. We have developed a graphical way 
to present the data (Fig. 6) which shows NDUFB8 and COX-I protein abundance in conjunction with 
mitochondrial mass in individual myofibres. This clearly summarises the degree and type of OXPHOS 
deficiency.
Patients with known mutations affecting complex I or IV activities specifically. Patients P1 (LRPPRC 
mutations; Fig. 6A, Supplementary Table S4) and P2 (MT-ND1 point mutation; Fig. 6B, Supplementary 
Table S4) showed isolated COX-I and NDUFB8 deficiencies respectively, in keeping with the biochemical 
defects assessed by spectrophotometric enzyme assay (Supplementary Table S5) and as predicted based 
on the known function of the mutated protein.
Single, large-scale mtDNA deletions. Patients harbouring single, large-scale mtDNA deletions (P3–P6, 
Fig. 6C–F) showed decreased abundance of both complex IV and complex I subunits with slightly more 
pronounced involvement of complex IV (Supplementary Table S4).
Multiple mtDNA deletions due to nuclear gene defects. Patients diagnosed with a nuclear-driven disor-
der leading to the accumulation of multiple mtDNA deletions in muscle (P7–P11, Fig. 6G–K) showed a 
greater proportion of fibres deficient in complex I than complex IV (Supplementary Table S4). All five 
patients presented a similar profile of biochemical deficiency: a discrete population of fibres that showed 
decreased NDUFB8 abundance without concomitant complex IV deficiency and a further, distinct pop-
ulation of myofibres in which subunits of both complex I and complex IV were equally down-regulated 
(Fig. 6G–K).
Patients
COX-I NDUFB8
Pos Int(+) Int(−) Neg Pos Int(+) Int(−) Neg n
P1  
(LRPPRC 
mutations)
Day 1 0.2% 3.8% 15.3% 80.7% 99.8% 0.2% 0.0% 0.0% 424
Day 2 0.2% 4.5% 17.3% 78.0% 99.6% 0.3% 0.1% 0.0% 1258
E (D1–D2) 0.1% − 0.8% − 2.0% 2.7% 0.2% − 0.1% − 0.1% − 
95% CI (D1–D2) − 0.4%, 0.6% − 2.9%, 1.4% − 6.0%, 2.0% − 1.7%, 7.1% − 0.4%, 0.7% − 0.6%, 0.5% − 0.2%, 0.1% − 
P2 
(m.4175G > A 
MT-ND1)
Day 1 99.9% 0.1% 0.0% 0.0% 9.6% 0.4% 0.2% 89.7% 823
Day 2 100.0% 0.0% 0.0% 0.0% 11.9% 0.3% 0.1% 87.8% 932
E (D1–D2) − 0.1% 0.1% − − − 2.3% 0.2% 0.1% 2.0%
95% CI (D1–D2) − 0.3%, 0.1% − 0.1%, 0.3% − − − 5.0%, 0.5% − 0.4%, 0.7% − 0.2%, 0.5% − 0.8%, 4.8%
P11 
(Multiple 
mtDNA 
deletions)
Day 1 72.8% 5.3% 3.2% 18.7% 63.4% 12.4% 4.7% 19.6% 1589
Day 2 71.2% 5.2% 2.7% 21.0% 54.4% 19.0% 4.1% 22.5% 2400
E (D1–D2) 1.7% 0.1% 0.5% − 2.3% 9.0% − 6.6% 0.6% − 2.9%
95% CI (D1–D2) − 1.2%, 4.5% − 1.3%, 1.5% − 0.6%, 1.6% − 4.8%, 0.3% 5.9%, 12.1% − 8.9%, − 4.4% − 0.7%, 1.9% − 5.5%, 0.3%
P17 
(m.5690A> G 
MT-TN)
Day 1 91.5% 1.0% 1.2% 6.2% 79.6% 7.1% 3.3% 10.0% 1362
Day 2 91.5% 1.1% 1.2% 6.2% 81.2% 5.9% 3.6% 9.3% 1512
E (D1–D2) 0.0% − 0.1% 0.1% 0.0% − 1.6% 1.2% − 0.3% 0.7%
95% CI (D1–D2) − 2.0%, 2.1% − 0.9%, − 0.7% − 0.8%, 0.9% − 1.8%, 1.8% − 4.5%, 1.3% − 0.6%, 3.0% − 1.6%, 1.1% − 1.5%, 2.8%
P18  
(Novel MT-
TP mutation)
Day 1 0.5% 1.1% 2.5% 95.9% 0.4% 0.5% 4.4% 94.7% 1012
Day 2 0.4% 0.9% 1.6% 97.0% 0.2% 0.4% 2.2% 97.2% 1689
E (D1–D2) 0.1% 0.1% 0.9% − 1.1% 0.2% 0.1% 2.3% − 2.6%
95% CI (D1–D2) − 0.5%, 0.6% − 0.7%, 0.9% − 0.3%, 2.0% − 2.6%, 0.4% − 0.2%, 0.7% − 0.5%, 0.6% 0.8%, 3.2% − 4.1%, − 1.0%
Table 2.  Quantification of COX-I and NDUFB8 deficiency in two serial skeletal muscle sections 
from 5 patients. Key: E (D1–D2) = estimate for difference between Day 1 and Day 2; 95% CI (D1-D2) 
= 95% confidence interval for the difference between Day 1 and Day 2; n = number of fibres quantified; 
Pos = positive, Int(+ ) = intermediate positive, Int(− ) = intermediate negative, Neg = negative.
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m.3243A>G MT-TL1 mutation. The profile of deficiency in patients with this mutation (P12–P16, 
Fig.  7L–P) was similar, with much more severely affected complex I than complex IV (Supplementary 
Table S4).
Other mt-tRNA mutations. Patient P22, carrying the m.3243A > T MT-TL1 mutation (Fig.  7V), had 
an OXPHOS deficiency similar to patients with m.3243A > G MT-TL1 mutation (P12–P16, Fig. 7L–P). 
P17 (m.5690A > G MT-TN mutation, Fig. 7Q) and P20 (m.14709T > C MT-TE mutation, Fig. 7T) also 
showed more complex I than complex IV deficiency, but with more evidence of complex IV involvement 
than in the case of patients with m.3243A > G MT-TL1 mutation (Supplementary Table S4). By contrast, 
P18 (Novel MT-TP mutation, unpublished, Fig. 7R), P19 (m.10010T > G MT-TG mutation, Fig. 7S) and 
P21 (m.5543T > C MT-TW mutation, Fig. 7U) demonstrated very high levels of deficiency.
Discussion
OXPHOS deficiency can be difficult to quantify accurately. We have developed a sensitive quadruple 
immunofluorescent technique which enables accurate quantification of key OXPHOS protein abundance 
(complex I and complex IV) and a mitochondrial mass marker (porin) in individual myofibres, all within 
a 10 μ m tissue section. Using laminin to define cell boundaries enables automatic quantification of myofi-
bres29. We demonstrate that this technique is sensitive and reliable in detecting and quantifying focal 
OXPHOS deficiency in human muscle, and show that different mitochondrial genotypes – both mtDNA 
and nuclear DNA driven - exhibit distinctive signatures of mitochondrial dysfunction. We also demon-
strate the precision and reproducibility of this technique, highlighting its potential not only as a diag-
nostic tool but also as a means to study mechanisms of disease, age-related changes, disease progression, 
and therapeutic interventions including exercise.
Advantages of the new quadruple immunofluorescent assay. COX/SDH histochemistry is 
commonly used to assess OXPHOS function in individual cells and is extremely useful to screen for 
signs of mitochondrial dysfunction7. We have demonstrated that, in cases of obvious COX deficiency, the 
visual classification of fibres was comparable with the objective immunofluorescence. In these instances, 
we have shown that COX-I protein abundance correlated well with COX activity, validating the use of 
immunofluorescence to evaluate the mitochondrial biochemical profile. However, in challenging cases, 
visual classification was inconsistent and significantly differed between investigators.
Objective and informatics-based assessment allows greater accuracy and consistency in results15,30–32. 
We have demonstrated that our protocol overcomes the mis-estimation of mitochondrial dysfunction 
due to subjectivity, tissue-specific artefacts (such as uneven labelling) and limitations attributable to 
human error, through collecting data on two separate occasions by two investigators. We have demon-
strated that this technique is reliable and reproducible by processing sections through the methodo-
logical protocol on two separate occasions. Additionally, the large numbers of experimental replicates 
conducted support the reproducibility of this technique, since all the controls demonstrated consistent 
Figure 4. Inter-observer variability of quadruple immunofluorescence. Quadruple immunofluorescence 
was performed in a muscle section taken from P8 (multiple mtDNA deletions) and approximately the same 
area of the biopsy was assessed by investigator 1 (n = 528 fibres analysed) and investigator 2 (n = 470 fibres 
analysed). The assessment included imaging the selected area of the muscle section by each investigator 
on a separate occasion (15 days apart) and performing subsequent IMARIS analysis. Bar graphs show the 
percentage of fibres with normal (beige), intermediate(+ ) (light beige), intermediate(− ) (light blue), and 
deficient (blue) levels of (A) COX-I and (B) NDUFB8, when assessed by investigators 1 and 2.
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Figure 5. Representative images of complex I and IV abundance in skeletal muscle sections from 
control and disease cases using quadruple immunofluorescence. Fluorescent detection was used to 
visualise: COX-I - green, NDUFB8 - purple, porin - red and laminin – white. Representative images of 
respiratory-normal tissue (disease control, DC1) and single large-scale mtDNA deletion (P6), multiple 
mtDNA deletions (P11), m.3243A > G MT-TL1 mutation (P16), m.5690A > G MT-TN mutation (P17), 
novel MT-TP mutation (P18), m.10010T > C MT-TG mutation (P19), m14709T > C MT-TE mutation (P20), 
m.5543T > C MT-TW mutation (P21) and m.3243A > T MT-TL1 mutation (P22). Representative images of 
compound heterozygous LRPPRC mutations and m.4175G > A MT-ND1 mutation are shown in Fig. 1. DC1 
is a paediatric case and thus has smaller fibre size than the other cases. Scale bars measure 50 μ m.
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Figure 6. Mitochondrial respiratory chain expression profile linking complex I, complex IV and 
porin levels in patients with genetically-characterised mitochondrial disease. Plots show complex I 
and IV expression profile from patients with (A) isolated complex IV deficiency (compound heterozygous 
LRPPRC mutations, P1, n = 1258fibres analysed), (B) isolated complex I deficiency (m.4175G > A MT-
ND1 mutation, P2, n = 1062), (C–F) single mtDNA deletion: (C) P3 (n = 1027), (D) P4 (n = 1228), (E) P5 
(n = 841) and (F) P6 (n = 779), (G–K) multiple mtDNA deletions: (G) P7 (n = 526), (H) P8 (n = 528), (I) 
P9 (n = 1071), (K) P10 (n = 1118) and (K) P11 (n = 2400), Each dot represents the measurement from an 
individual muscle fibre, colour coded according to its mitochondrial mass (very low: blue, low: light blue, 
normal: light orange, high: orange and very high: red). Thin black dashed lines indicate the SD limits for 
the classification of fibres, lines next to x and y axis indicate the levels of NDUFB8 and COX-I respectively 
(beige: normal, light beige: intermediate(+ ), light blue: intermediate(− ) and blue: deficient). Bold dashed 
lines indicate the mean expression level of normal fibres.
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Figure 7. Continuation of figure 6. Plots show complex I and IV expression profile from patients with 
(L–P) m.3243A > G MT-TL1 mutation: (L) P12 (n = 1328), (M) P13 (n = 499), (N) P14 (n = 1441), (O) P15 
(n = 741) and (P) P16 (n = 918) and (Q–V) different mt-RNA mutations: (Q) m.5690A > G MT-TN mutation 
(P17, n = 1512), (R) novel MT-TP mutation (P18, n = 1012), (S) m.10010T > G MT-TG mutation (P19, 
n = 769), (T) m.14709T > C MT-TE mutation (P20, n = 1782), (U) m.5543T > C MT-TW mutation (P21, 
n = 447) and (V) m.3243A > T MT-TL1 mutations (P22, n = 1042).
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and comparable levels of protein abundance, and importantly, almost all patients exhibited at least a 
small population of fibres with Z-scores centred appropriately around the mean NDUFB8 and COX-I 
levels observed in the controls.
Previous studies have elegantly explored the involvement of multiple OXPHOS complexes using 
immunohistochemistry for the diagnosis and understanding of mitochondrial pathology33–37, but there 
have been limited studies to quantify the deficiency28,35,38. Our method quantitates mitochondrial protein 
abundance using a single muscle section, avoiding potential confounds of section thickness variance and 
changing biochemical profiles along myofibres28,39–41.
Though our data demonstrates the close association of COX-I abundance and COX enzymatic activ-
ity, there is no histochemical assay for complex I able to accurately measure activity in single muscle 
fibres, making validation for this complex difficult. However, it has been shown that mutations in many 
subunits of the OXPHOS complexes lead to assembly defects or affect complex stability, leading to deg-
radation of the unintegrated proteins42,43. Importantly, NDUFB8 has been shown to be essential to the 
functional enzymatic activity of Complex I23, and thus reduced protein abundance can reliably be inter-
preted as lowered enzymatic activity.
Biochemical phenotype of different mitochondrial genetic defects. We have shown that spe-
cific genotypes present similar patterns of mitochondrial deficiency, consistent with the known bio-
chemical defect. For example, patients harbouring compound heterozygous LRPPRC mutations showed 
isolated COX deficiency44–46, whilst the patient carrying the m.4175G > A MT-ND1 mutation showed 
isolated complex I deficiency47–50.
Patients with single, large-scale mtDNA deletions show a simultaneous loss of both complex I and 
complex IV, consistent with both the lack of mtDNA encoded structural subunits of OXPHOS complexes 
and the loss of several mt-tRNAs. Though all single deletion patients demonstrated simultaneous loss of 
both complexes, there is variation in the linear direction or curve of decline between patients, suggesting 
differential rates of COX-I decline in comparison to NDUFB8, possible related to the site and size of 
the deletions51.
Patients with nuclear gene mutations leading to a disturbance of mtDNA maintenance demonstrated 
a similar pattern of enzyme deficiency, independent of the underlying molecular genetic defect. The 
nature of the biochemical defect in these muscle biopsies is different from that seen in biopsies from 
patients with single, large-scale mtDNA deletions, compatible with previous reports52. The presence of 
fibres with complex I deficiency is consistent with reports of the loss of complex I structural genes in the 
deleted molecules53,54, although further molecular studies are necessary to correlate the biochemical and 
molecular phenotype in individual myofibres55.
Mutations in mtDNA-encoded tRNA genes are associated with impaired mtDNA-encoded protein 
translation, leading to multiple OXPHOS defects. Interestingly, patients with the common m.3243A > G 
MT-TL1 mutation demonstrate a pattern of deficiency (the distinctive (rotated) L shape seen repeatedly 
in Fig.  7L–P) suggesting that complex IV is only affected after complex I deficiency is already estab-
lished, consistent with previous observations56. This pattern also indicates that the deficiency is smoothly 
graduated from normal to deficient levels of both complexes, contrasting with the polarised pattern 
observed in the MT-ND1 mutation. As patients with this mutation demonstrate highly variable clinical 
manifestations, it would be interesting to see if this technique can reveal a correlation between clinical 
and biochemical phenotypes57. The patient carrying a transversion mutation at this site, m.3243A > T 
MT-TL1, showed the same pattern of deficiency, despite being reported to present a higher deleterious 
effect on translation58. However, there are several potential confounders to any interpretation of the 
severity of the defect, not least heteroplasmy.
Rarer mt-tRNA point mutations revealed other distinct patterns of deficiency. Though the mutations 
studied in MT-TN and MT-TE show the same pattern of deficiency as seen in the MT-TL1 mutations, 
those in MT-TG and MT-TP instead suggested simultaneous decline in both complex I and complex IV 
protein abundance. A third distinctive pattern is seen in the MT-TW mutation; although severe defi-
ciency is observed in both complexes, the deficiency in complex IV appears to plateau at a level much 
higher than observed in other mt-tRNA point mutations. Additionally, though the majority of fibres 
with complex IV deficiency demonstrated that COX-I abundance has declined to a specific basal level, 
a wide range of NDUFB8 deficiency is observed across the same fibres. This suggests that the relative 
rate of decline in complex I and complex IV protein levels varies considerably from fibre to fibre for this 
mutation, an effect not observed in other mt-tRNA point mutations.
For all the mtDNA mutations, future investigations are required to correlate the observed biochem-
ical profile with heteroplasmy levels, and similarly, for mt-tRNA mutations specifically, the correla-
tion of the biochemical profile with the relative amounts of the cognate amino acid within each of the 
mtDNA-encoded complex I and IV proteins.
Technical methodology. A major and recurrent problem when performing immunofluorescence 
is signal from non-specific binding of secondary antibodies. Several research groups have developed 
strategies to mitigate these effects, usually by manually setting an intensity threshold to identify positive 
cells59,60. Nevertheless this threshold is subjective. For our analyses, the non-specific signal was objectively 
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measured on the NPC and subtracted from the intensities measured on the quadruple immunofluo-
rescence. We found that the secondary antibody (IgG1 biotinylated) coupled with NDUFB8 showed a 
higher affinity in fibres with high porin abundance, evident from higher intensity fluorescence on the 
NPC. We identified that this off-target binding was associated with the anti-IgG1secondary antibody and 
not the fluorophore (Alexa Fluor 647), since exchanging the secondary antibody fluorophores resulted in 
the increased NPC signal switching to the alternate fluorophore (Alexa Fluor 546).
To compensate for this effect and ensure the NDUFB8 values represent true signal, the ODNDUFB8 
signal were corrected according to mitochondrial mass. This approach was validated by the fact that, 
without correction, ragged red fibres (which have dense mitochondrial mass and hence porin, but 
low abundance of COX-I and NDUFB861) demonstrated constant basal levels of COX-I signal but 
ODNDUFB8 signal proportional to the ODporin. With correction the ODNDUFB8 in ragged red fibres 
was at a constant basal level consistent with the COX-I abundance and no increasing trend with ODporin 
was observed for either OXPHOS protein.
A supporting tool written in R24 to automate the analysis is available on request.
Conclusion
We have developed an objective, reliable and high-throughput quantification technique that allows 
assessment of complex I and complex IV protein abundance relative to mitochondrial mass in individ-
ual fibres from patients with mitochondrial myopathies using a single (10 μ m) muscle section. This work 
has yielded important insights into the nature of the biochemical defects in patients with mitochondrial 
dysfunction. We believe this new technique has important implications for the diagnosis and treatment 
of mitochondrial diseases and other diseases with mitochondrial involvement, as well as investigating the 
molecular mechanisms underlying these conditions.
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